# Bioequivalence Bewteen DopaSnap® (Cabidopa/Levopdoap 25/100 mg Tablet) and Carbidopa/Levodopa 25/100 mg Tablet (Actavis)

> **NCT04236921** · PHASE1 · COMPLETED · sponsor: **Riverside Pharmacueticals Corporation** · enrollment: 57 (actual)

## Conditions studied

- Other

## Interventions

- **DRUG:** DopaSnap®
- **DRUG:** RDL of CD-LD

## Key facts

- **NCT ID:** NCT04236921
- **Lead sponsor:** Riverside Pharmacueticals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-15
- **Primary completion:** 2019-09-11
- **Final completion:** 2019-12-01
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2020-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04236921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04236921, "Bioequivalence Bewteen DopaSnap® (Cabidopa/Levopdoap 25/100 mg Tablet) and Carbidopa/Levodopa 25/100 mg Tablet (Actavis)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04236921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*